Skip to main content
. Author manuscript; available in PMC: 2012 Jun 15.
Published in final edited form as: Clin Cancer Res. 2011 May 10;17(12):4101–4109. doi: 10.1158/1078-0432.CCR-11-0407

Figure 1. Immunohistochemical analysis of CD8+ cell infiltration before and after tremelimumab in four representative patients.

Figure 1

Specimens of pre- and post-tremelimumab tumor biopsies from two patients who went onto have a durable complete response after tremelimumab (GA18 and GA29) are compared with two representative samples of patients who had disease progression after therapy (GA12 and GA14). Even though there were no intact melanoma cells evident in the post-dosing sample GA18, the histological changes supported that the biopsy derived from a regressing lesion with lymphocytic infiltrates and the values for this case are considered as intratumoral infiltration.